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Materials and methods: 110 pregnant rats were used in this study: 
untreated (control) rats (n=42), rats orally treated with nebivolol (8 mg/kg/day, 
n=43), or bisoprolol (10 mg/kg/day, n=25) from day 11 to day 18 of gestation. 
The systolic blood pressure (SBP) and genital blood flow (GBF) were mea-
sured by tail cuff method and transonic method respectively (on the 19th day 
and 20th of the gestation). In addition, a morphometric study was performed 
on the ovarian and uterine arteries; fetal weight and postnatal development of 
three infants randomly chosen are following for 8 weeks. The results are 
expressed as mean ± SEM of n experiments.
Results: The results clearly showed that SBP and GBF are lower in rats 
treated with nebivolol (SBP=115.56 ± 0.62 mmHg. GBF= 0.20 ± 0.04 ml/s) 
compared to untreated rats (SBP=140.14 ± 0.33 mmHg. GBF=0.53±0.03 ml/s) or 
to that treated with bisoprolol (SBP=122.42 ± 0.28. GBF=0.40±0.03). The 
treatment with nebivolol also caused a strong increase of lengths and diame-
ters of the ovarian and uterine arteries. In addition, it increases the number of 
segmental branches of the uterine artery compared to the other two groups. 
Moreover, the results showed that nebivolol has an adverse impact on fetal 
growth and postnatal development. It was found that average weight of a fetus 
at the end of gestation was (3.55 ± 0.03 g) with nebivolol, (5.64 ± 0.01 g) with 
bisoprolol and (6.05 ± 0.02 g) in control.
Conclusion: We showed that the action of nebivolol is not only limited to 
its favorable hemodynamic effects, but nebivolol also produces adverse effects 
on fetal growth and postnatal development, that may limit its therapeutic use 
during pregnancy. As wistar female rats were normotensive, we need to fur-
ther investigate the effect of nebivolol in a hypertensive model.
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Objective: Hypertension is a frequent side effect of antiangiogenic drugs 
(AAD). Targeting VEGF pathway may also affect large and small artery prop-
erties, along with or independently of blood pressure changes. We hypothe-
sized that large and small artery property changes in response to AAD reflect 
their effect on the microcirculation at the site of the tumor, and thus may be 
related to cancer progression and mortality.
Design and method: We included 60 patients [age 58 (15) years, mean 
SBP 127(21) mmHg] in whom treatment with AAD was indicated for various 
metastatic solid tumors. Noninvasive arterial investigation was performed 
before AAD (V0), 1 week later (V1) and then every two weeks for two 
months (V1 to V4): carotid-femoral pulse wave velocity (cfPWV), central 
SBP and augmentation index (cAIx) by applanation tonometry (Sphyg-
moCor®), and carotid stiffness (CStiff) and internal diameter (CiD) by high 
resolution echotracking (Artlab®). Cancer progression and mortality were 
assessed at 6 months.
Results and conclusion: 28(47%) patients developed hypertension during 
follow-up. bSBP significantly increased during follow-up (V0-V1: +9.3± 
15.2mmHg, P<0.001; V0-V4: +6.0±17.8mmHg, P=0.03), as well as PWV, 
CStiff, and CiD. Baseline cAIx predicted cancer progression (RR=0.73 per 
10%) and mortality (RR=0.73 per 10%, P<0.001) while SBP did not. The V0-
V1 increase in CStiff predicted cancer progression (RR=1.37 per 1 m/s, 
P=0.02), independently of age and MBP. In conclusion, increased AIx and 
arterial stiffness, but not brachial or central SBP, were related with the effects 
of AAD on cancer progression and mortality.
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Introduction: Renal denervation is an endovascular technique of sympa-
thetic afferences ablation, currently indicated in resistant hypertension.
Objective: According to the European guidelines, it should be part of a 
comprehensive therapeutic approach and the object of a multidisciplinary 
decision. To this purpose, we evaluated our professional practices by ana-
lyzing our one-year program of screening for eligible patients.
Patients and Method: Between Oct 2012 and Oct 2013, 10 interdisci-
plinary reunions including vascular doctors, nephrologists, radiologists and 
cardiologists took place at the University Hospital of Strasbourg, reviewing 
41 cases of resistant hypertension.
Results: The characteristics of the 41 patients were the following: a mean 
age of 62±9 years old (mean±SEM), predominantly male (66%), a glomerular 
filtration rate of 67±23 ml/min/1,73 m2 and an ambulatory blood pressure 
(ABPM) daytime mean of 152/83mmHg±15/14 while receiving 4±1 anti-
hypertensive drugs daily. Among them, 9 were controlled after adjustment of 
medical treatment, 5 had a renal artery stenosis, 4 had a fibromuscular dys-
plasia; there were 2 severe renal impairments and 11 other morphologic exclu-
sion criteria. The 10 patients who finally benefitted from renal denervation 
had an initial daytime ABPM of 164/93±11/11 mmHg and an initial office 
blood pressure of 174/94±18/23mmHg while receiving 5,2±0.6 antihyperten-
sive drugs. The follow up visits showed a mean reduction in the office blood 
pressure of 11.5mmHg ±18 at 1 month (n = 9), of 10.5mmHg ±10 at 3 months 
(n = 7) and 14mmHg ±25 at 6 months(n = 5).
Conclusion: Renal denervation is an invasive procedure claiming to 
become part of the armamentarium of antihypertensive treatments, requiring 
trained operators and prior careful evaluation in order to eliminate remediable 
causes of treatment resistance. Our preliminary results are mitigated showing 
a stable and significant resp
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